Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.
about
Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer.Third generation EGFR TKIs: current data and future directions.The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.The continued EGFR-TKI with cytotoxic chemotherapy at progression-poison or medicine?
P2860
Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Overcoming Acquired Resistance ...... ent Bim and Mcl-1 Degradation.
@en
Overcoming Acquired Resistance ...... ent Bim and Mcl-1 Degradation.
@nl
type
label
Overcoming Acquired Resistance ...... ent Bim and Mcl-1 Degradation.
@en
Overcoming Acquired Resistance ...... ent Bim and Mcl-1 Degradation.
@nl
prefLabel
Overcoming Acquired Resistance ...... ent Bim and Mcl-1 Degradation.
@en
Overcoming Acquired Resistance ...... ent Bim and Mcl-1 Degradation.
@nl
P2093
P2860
P1476
Overcoming Acquired Resistance ...... ent Bim and Mcl-1 Degradation.
@en
P2093
Benjamin Legendre
Emily Anderson
Guojing Zhang
Guoqing Qian
Liang Deng
Mingwei Chen
Shi-Yong Sun
P2860
P304
P356
10.1158/1078-0432.CCR-17-1574
P407
P577
2017-08-01T00:00:00Z